Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months

Vaccine

Volumn 29, Issue 27, 2011, Pages 4499-4506

  Russell, F M ^a   Balloch, A ^b   Licciardi, P V ^b   Carapetis, J R ^c   Tikoduadua, L ^d   Waqatakirewa, L ^d   Cheung, Y B ^e,f   Mulholland, E K ^c,g   Tang, M L K ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d Ministry of Health   (Fiji)

^e SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Infant pneumococcal vaccination; Pneumococcal antibody avidity

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPB; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS CONJUGATED VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AGE SPECIFIC CARE; ARTICLE; CHILD; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG CONJUGATION; DRUG DOSE INCREASE; DRUG RESPONSE; HUMAN; IMMUNIZATION; INFANT; KINETICS; MAJOR CLINICAL STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INFANT; KINETICS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; SINGLE-BLIND METHOD; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 79958146149     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.038     Document Type: Article

References (30)

1. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007;82(12):93-104 [March 23].
2. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(September (9693)):893-902.
3. Jin P., Kong F., Xiao M., Oftadeh S., Zhou F., Liu C., et al. First report of putative streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian Children. J Infect Dis 2009 Nov 1, 200(9):1375-1380.
4. Park I.H., Pritchard D.G., Cartee R., Brandao A., Brandileone M.C., Nahm M.H. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007, 45(April (4)):1225-1233.
5. GAVI's PneumoADIP. Department of International Health. Health. JHBSoP. Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP; 2008.
6. Jodar L., Butler J., Carlone G., Dagan R., Goldblatt D., Kayhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21(July (23)):3265-3272.
7. Goldblatt D., Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilusinfluenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998, 177(April (4)):1112-1115.
8. Granoff D.M., Anderson E.L., Osterholm M.T., Holmes S.J., McHugh J.E., Belshe R.B., et al. Differences in the immunogenicity of three Haemophilusinfluenzae type b conjugate vaccines in infants. J Pediatr 1992, 121(August (2)):187-194.
9. Usinger W.R., Lucas A.H. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999, 67(May (5)):2366-2370.
10. Wuorimaa T.K., Dagan R., Bailleux F., Haikala R., Ekstrom N., Eskola J., et al. Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine. Vaccine 2005, 23(November (46-47)):5328-5332.
11. Anttila M., Eskola J., Ahman H., Kayhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999, 17(April (15-16)):1970-1977.
12. Anttila M., Eskola J., Ahman H., Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998, 177(June (6)):1614-1621.
13. Ekstrom N., Ahman H., Verho J., Jokinen J., Vakevainen M., Kilpi T., et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun 2005, 73(January (1)):369-377.
14. Goldblatt D., Southern J., Ashton L., Richmond P., Burbidge P., Tasevska J., et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006, 25(April (4)):312-319.
15. Lee L.H., Frasch C.E., Falk L.A., Klein D.L., Deal C.D. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 2003, 21(May (17-18)):2190-2196.
16. Schlesinger Y., Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilusinfluenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992, 267(March (11)):1489-1494.
17. Granoff D.M., Lucas A.H. Laboratory correlates of protection against Haemophilusinfluenzae type b disease. Importance of assessment of antibody avidity and immunologic memory. Ann N Y Acad Sci 1995, 754(March):278-288.
18. Lucas A.H., Granoff D.M. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilusinfluenzae type B polysaccharide-protein conjugates. J Immunol 1995, 154(April (8)):4195-4202.
19. Russell F.M., Carapetis J.R., Tikoduadua L., Paeds D., Chandra R., Seduadua A., et al. Invasive pneumococcal disease in Fiji: clinical syndromes, epidemiology, and the potential impact of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010, 29(September (9)):870-872.
20. Russell F.M., Balloch A., Tang M.L., Carapetis J.R., Licciardi P., Nelson J., et al. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine 2009, 27(September (41)):5685-5691.
21. Russell F.M., Licciardi P.V., Balloch A., Biaukula V., Tikoduadua L., Carapetis J.R., et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 2010, 28(April (18)):3086-3094.
22. Russell F.M., Carapetis J.R., Balloch A., Licciardi P.V., Jenney A.W., Tikoduadua L., et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 2010, 28(April (19)):3341-3349.
23. Nahm MH, Goldblatt D. Training manual for enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA); .; 2006 [Journal serial on the internet]. http://www.vaccine.uab.edu/ELISA%2520Protocol.pdf.
24. Balloch A., Licciardi P.V., Leach A., Nurkka A., Tang ML Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance. Vaccine 2010, 28(5):1333-1340.
25. Wuorimaa T., Dagan R., Vakevainen M., Bailleux F., Haikala R., Yaich M., et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 2001, 184(November (9)):1211-1215.
26. Goldblatt D, Akoto A, Ashton L, et al., editors. Immunogenicity and the generation of immune memory following 9-valent pneumococcal conjugate vaccination in Ghanaian infants with sickle cell disease. 40th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario, Canada; 2000 September 24-27.
27. Anttila M., Voutilainen M., Jantti V., Eskola J., Kayhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol 1999, 118(December (3)):402-407.
28. Balloch A., Licciardi P., Russell F., Burton R., Nahm M., Mulholland K., et al. Does serotype-specific IgG and avidity to Streptococcus pneumoniae following infant immunisation correlate with functional opsonophagocytic activity?. 6th International Symposium on Pneumococci and Pneumococcal Diseases 2008.
29. Russell F.M., Carapetis J.R., Burton R.L., Lin J., Licciardi P.V., Balloch A., et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 2011, 29(January (3)):535-544.
30. Licciardi P.V., Balloch A., Russell F.M., Mulholland E.K., Tang M.L.K. Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization. Vaccine 2010, 28(May (22)):3793-3800.